Cancers & treatments·Regimen libraryLater line

Inotuzumab ozogamicin

Checked 2026-09-09

Relapsed or refractory CD22-positive B-ALL

One cycle

every 21 days

21-day cycle, up to 6 (2-3 if proceeding to transplant)Intravenous

Components

Drug	Dose	Route	Days	Note
Inotuzumab ozogamicin ADC	0.8 mg/m² day 1, 0.5 mg/m² days 8 and 15 (cycle 1); 0.5 mg/m² all doses once in remission	IV	D1, 8, 15

Cycles

up to 6 (2-3 if proceeding to transplant)

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Veno-occlusive disease after transplant: limit to 2 cycles and avoid dual-alkylator conditioning.

Used in

Acute lymphoblastic leukaemia

Trials

INO-VATE ALL

Products

Inotuzumab ozogamicin

Source

INO-VATE, NEJM 2016

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Blinatumomab

B-ALL: MRD-positive, relapsed/refractory, or consolidation in frontline regimens (E1910, AALL1731)

every 42 days × 2

Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T

Relapsed or refractory large B-cell lymphoma (second line if refractory or relapse within 12 months), B-ALL, follicular and mantle cell lymphoma

every 6 days

Imatinib

Chronic-phase CML; adjuvant GIST for 3 years after resection of high-risk tumours; metastatic GIST

every 28 days

Hyper-CVAD

Adult acute lymphoblastic leukaemia (with a tyrosine kinase inhibitor if Philadelphia-positive), Burkitt lymphoma and younger patients with mantle cell lymphoma

every 21 days × 8

All regimens Fludarabine + cyclophosphamide lymphodepletion, then CD19 CAR-T →